Robert Azelby
Director/Board Member chez ADC THERAPEUTICS SA
Fortune : 233 927 $ au 31/03/2024
Profil
Robert W.
Azelby is currently serving as a Non-Executive Director at ADC Therapeutics SA, Autolus Therapeutics Plc, and Cardinal Health, Inc. He previously held positions as the President, Chief Executive Officer & Director at Lundbeck Seattle BioPharmaceuticals, Inc. and Eliem Therapeutics, Inc. He also served as a Director at Immunomedics, Inc. and Cascadian Therapeutics LLC.
Additionally, he was an Independent Director at Clovis Oncology, Inc. and held various roles at Amgen, Inc., including Vice President & General Manager-Oncology.
He was also the Chief Commercial Officer & Executive VP at Juno Therapeutics, Inc. Mr. Azelby received his undergraduate degree from the University of Virginia and an MBA from Harvard Business School in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CARDINAL HEALTH, INC.
0,00% | 15/03/2024 | 1 288 ( 0,00% ) | 144 127 $ | 31/03/2024 |
ADC THERAPEUTICS LTD
0,02% | 02/01/2024 | 20 000 ( 0,02% ) | 89 800 $ | 31/03/2024 |
ELIEM THERAPEUTICS, INC.
-.--% | 31/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Robert Azelby
| Sociétés | Poste | Début |
|---|---|---|
| ADC THERAPEUTICS SA | Director/Board Member | 14/06/2023 |
| AUTOLUS THERAPEUTICS PLC | Director/Board Member | 09/01/2024 |
| CARDINAL HEALTH, INC. | Director/Board Member | 01/03/2024 |
Anciens postes connus de Robert Azelby
| Sociétés | Poste | Fin |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | 11/08/2023 |
| CLOVIS ONCOLOGY, INC. | Director/Board Member | 10/07/2023 |
| ELIEM THERAPEUTICS, INC. | Chief Executive Officer | 13/02/2023 |
| IMMUNOMEDICS, INC. | Director/Board Member | 23/10/2020 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Director/Board Member | 02/10/2019 |
Formation de Robert Azelby
| University of Virginia | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| CARDINAL HEALTH, INC. | Distribution Services |
| ADC THERAPEUTICS SA | Health Technology |
| AUTOLUS THERAPEUTICS PLC | Health Technology |
| ELIEM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Amgen Europe BV
 Amgen Europe BV Medical DistributorsDistribution Services Part of Amgen, Inc., Amgen Europe BV wholesales pharmaceutical products. The private company is based in Breda, Netherlands. | Distribution Services |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
